CA-NETAPP
28.8.2024 22:16:33 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the original intelligent data infrastructure company, today announced new capabilities that support VMware Cloud Foundation deployments. Mutual customers will be able to leverage NetApp solutions to right-size their IT environments to run VMware workloads at scale efficiently.
For more than a decade, NetApp and VMware, recently acquired by Broadcom Inc., have collaborated to ensure the success of their joint customers and help them unlock the full value of their VMware investments. During that time, NetApp has been a key engineering design partner with VMware and is continuing to drive innovation in highly available, scalable and performant storage as a design partner for its Next-Generation vSphere Virtual Volumes (vVols). Now, NetApp is announcing new capabilities that will enable joint customers to run their VMware deployments more efficiently.
“NetApp and Broadcom are working together to take the uncertainty out of hybrid cloud environments,” said Jonsi Stefansson, Senior Vice President and Chief Technology Officer at NetApp. “More than 20,000 customers rely on NetApp to support their VMware workloads. NetApp's continued close collaboration with Broadcom following the acquisition of VMware ensures our solutions seamlessly interoperate so our mutual customers can leverage a single intelligent data infrastructure to operate their VMware workloads more efficiently.”
NetApp is helping optimize costs, simplify operations, and increase flexibility for customers running VMware environments by offering:
- Expanded Support for VMware Cloud Foundation (VCF): NetApp and Broadcom customers will now be able to simplify their VCF hybrid cloud environments by using NetApp ONTAP® software for all storage requirements, including standard and consolidated architectures. The latest release of ONTAP Tools for VMware (OTV) will support SnapMirror® active sync to provide symmetric active-active data replication capabilities for NetApp storage systems running VMware workloads. SnapMirror active sync allows customers to operate more efficiently by offloading data protection from their virtualized compute and improving data availability.
- New Capabilities for Azure VMware Solution (AVS): To support customers that are extending or migrating their vSphere workloads to the cloud, customers can now leverage Spot Eco by NetApp with AVS reserved instances to get the most value out of their deployments. Using Spot Eco to manage AVS reserved instances while also using Azure NetApp Files to offload data storage can reduce compute costs significantly.
- Enhanced VM Optimization Features for NetApp Cloud Insights: NetApp is introducing Cloud Insights VM Optimization, expanding its comprehensive solution for optimizing virtual environments, including VMware. Cloud Insights VM Optimization will give customers tools to reduce costs by increasing VM density, run storage at the best price-to-performance ratio for their environment, and monitor their entire environment to ensure availability, performance, and adherence to configuration best practices across the entire stack. To help customers optimize the compute, memory and storage resources of their VMware environments, NetApp is also offering customers a free 30-day trial of Cloud Insights to most cost-effectively migrate to the new VMware software subscriptions.
These offerings follow last month’s release of enhancements to NetApp BlueXP™ disaster recovery service, which provides guided workflows to design and execute automated disaster recovery plans for VMware workloads across hybrid cloud environments with newly added support for VMFS datastores.
“As organizations modernize infrastructure with VMware Cloud Foundation, they want to know that the services upon which they rely from industry-leaders such as NetApp will continue to work seamlessly and deliver the value they have come to expect,” said Paul Turner, Vice President of Products, VCF Division at Broadcom. “Having NetApp as a close collaborator helps our mutual customers deploy innovative data and storage services on top of their private cloud platform, and ensure they are getting the most value out of their VMware environments.”
“We have made Microsoft Azure the cloud of choice for VMware environments and offer fast and cost-effective solutions enabling many customers to move their VMware workloads to the cloud,” said Brett Tanzer, Vice President of Product Management at Microsoft. “As VMware customers navigate changes to operating virtualized environments, we have given our customers a way to lock in secure and predictable pricing over multiple years. NetApp's data management and cloud observability capabilities help our customers ensure those deployments are delivering the return on investment they need.”
“In an ever more complicated world of cloud, data, and infrastructure operations, IT teams are increasingly looking for holistic platforms over point solutions,” said Scott Sinclair, Practice Director, Enterprise Strategy Group. “These joint updates from NetApp and Broadcom enable customers to use NetApp’s intelligent data infrastructure to consolidate multiple data operations onto a single platform with industry-leading data management and CloudOps capabilities. That will help customers drive greater operational and infrastructure efficiencies that reduce the total cost of ownership for their VMware investments.”
Additional Resources
About NetApp
NetApp is the original intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828604243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom